Metabolic adverse drug events of antidepressants associated with the serotonin-2C receptor gene: a prospective follow-up study - MAAS-study

Maaslandziekenhuis0 个研究点目标入组 100 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•- Abnormal clinical outcomes at the first health check in which a consult with the general practitioner is advised. These outcomes are:
•- BMI * 30 kg/m2
•- Total cholesterol * 8 mmol/l
•- Total cholesterol * 4.5 mmol/l + diabetes
•- LDL * 2.5 mmol/l + * 1 risk factor
•- Systolic blood pressure * 140 mmHg + * 1 risk factor
•- Systolic blood pressure * 160 mmHg
•- Glucose > 7.8 mmol/l + BMI * 25 kg/m2
•(Risk factors are: smoking, diabetes mellitus, family anamnesis (father, mother, brother or sister) with cardiovascular disease before the age of 60 years.)
•- Use of the antidepressant is shorter than 105 days
•- Use of other antidepressants during the study period: citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, mianserin, paroxetine, trazodone, venlafaxine, buprorion, amitriptyline, clomipramine, dosulepin, doxepine, imipramine, maprotiline, nortripyline
•- Use of atypical antipsychotics during the study period: aripiprazole, clozapine, olanzapine, risperidone, quitiapine, sertindol

发起方

Maaslandziekenhuis